RVL Pharmaceuticals Posts Double-Digit Q3 Revenue Growth on Upneeq
Image
Bridgewater, N.J. – October 30, 2026 -- RVL Pharmaceuticals reported double-digit year-over-year revenue growth in the third quarter, driven by rising consumer demand for its prescription eye drop Upneeq, a national celebrity campaign and a widened product line.
Upneeq anchors RVL's vertically integrated platform
Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%) treats acquired blepharoptosis, or low-lying eyelids. It is the core asset of RVL's omnichannel platform, which combines consumer demand generation, healthcare provider engagement, telemedicine, pharmacy fulfillment and data-driven insights. RVL puts the total addressable market for Upneeq at an estimated $2.5 billion.